Aura Biosciences, Inc.
AURA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AURA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AURA
Aura Biosciences, Inc. is a clinical-stage biopharmaceutical company developing belzupacap sarotal (AU-011), a virus-like drug conjugate for the treatment of ocular cancers, with a Phase 3 trial ongoing and cash runway expected into the first half of 2029.
Key risk: Clinical trial delays or failure
BioSniper Score
Based on 6 of 6 signals
Market Cap
$767.4M
Cash Runway
13.5 moLead Asset
Bel-sar (Phase 3)
Next Catalyst
Phase3_Topline · Aug 15, 2028Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 10 clinical trials · 1 catalyst for Aura Biosciences, Inc..
Aura Biosciences, Inc. is a clinical-stage biopharmaceutical company developing belzupacap sarotal (AU-011), a virus-like drug conjugate for the treatment of ocular cancers, with a Phase 3 trial ongoing and cash runway expected into the first half of 2029.
- Cash & equivalents of $68.6M as of 2026-06-30 [sec].
- Net loss of -$45.6M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $174.6M as of 2026-06-30 [sec].
- Expected cash runway into the first half of 2029 [sec · filed 2026-08-11].
- Phase 3 trial of belzupacap sarotal (AU-011) is ongoing, with topline data expected on 2028-08-15 [catalyst].
What works
- Cash runway extended into the first half of 2029, providing funding through key clinical milestones [sec · filed 2026-08-11].
- Phase 3 trial of belzupacap sarotal is underway, targeting a significant unmet need in ocular oncology [catalyst].
- Shareholders' equity of $174.6M as of 2026-06-30 indicates a solid capital base [sec].
What to weigh
- Net loss of -$45.6M for the six months ended 2026-06-30 reflects ongoing operating expenses without product revenue [sec].
- The company is pre-revenue and depends on successful clinical development and regulatory approval for future income [sec].
- Clinical trials are inherently uncertain; delays or negative results could materially affect the company's prospects [sec · filed 2026-08-11].
From the filings
Quoted directly from source documents.
Cash runway into first half of 2029
“the Company's expected cash runway into the first half of 2029”
SEC filings · August 11, 2026
Catalyst timeline
- 2028-08-15 · Phase3_Topline — Topline data from the Phase 3 trial of belzupacap sarotal will be released, which is a key efficacy and safety readout.
Risks & what to watch (4)›
Key risks
- Clinical trial delays or failure — Phase 3 trial may be delayed or produce negative results, impacting stock and pipeline [sec · filed 2026-08-11].
- No approved products or revenue — Company has no marketed products and relies on future regulatory approval for revenue [sec].
- Cash burn rate — Net loss of $45.6M in six months indicates significant cash consumption [sec].
- Regulatory and competitive risks — Uncertainties in FDA approval and competition from other ocular therapies [sec · filed 2026-08-11].
What to watch
- Phase 3 topline data for belzupacap sarotal expected on 2028-08-15 [catalyst].
- Cash runway updates and quarterly financial reports to monitor burn rate [sec · filed 2026-08-11].
- Any regulatory interactions or updates on the clinical trial progress [sec].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Aura Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aura Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
13.5 months
D/E 0.10 · 0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~716d
0 buys · 3 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
123
Total value held
$255.3M
| Holder | Shares | Value |
|---|---|---|
| matrix capital management company, lp | 6,922,870 | $46.3M |
| adage capital partners gp, l.l.c. | 4,881,125 | $32.7M |
| vanguard capital management llc | 4,487,656 | $30.0M |
| suvretta capital management, llc | 4,372,884 | $29.3M |
| blackrock, inc. | 3,586,640 | $24.0M |
| franklin resources inc | 2,072,726 | $13.9M |
| geode capital management, llc | 1,310,862 | $8.8M |
| millennium management llc | 1,097,627 | $7.3M |
| state street corp | 964,670 | $6.5M |
| levin capital strategies, l.p. | 941,400 | $6.3M |
Showing top 10 of 123 institutional holders of Aura Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.7%
- Days to cover
- 7.2
- Shares short
- 2,192,556
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AURA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aura Biosciences, Inc.?
Aura Biosciences, Inc. is a clinical-stage biopharmaceutical company developing belzupacap sarotal (AU-011), a virus-like drug conjugate for the treatment of ocular cancers, with a Phase 3 trial ongoing and cash runway expected into the first half of 2029.
What is Aura Biosciences, Inc.'s lead drug candidate?
Aura Biosciences, Inc.'s most advanced tracked candidate is Bel-sar (Phase 3) for Choroidal Melanoma.
What is Aura Biosciences, Inc.'s next catalyst?
Aura Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotal" — expected August 15, 2028.
Who is the CEO of Aura Biosciences, Inc.?
Ms. Natalie C. Holles is the chief executive officer of Aura Biosciences, Inc. (AURA).
Where is Aura Biosciences, Inc. headquartered?
Aura Biosciences, Inc. (AURA) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.